Safety and effectiveness of butorphanol in epidural labor analgesia:A protocol for a systematic review and meta-analysis

BACKGROUND Epidural analgesia is the most effective analgesic method during labor.Butorphanol administered epidurally has been shown to be a successful analgesic method during labor.However,no comprehensive study has examined the safety and efficacy of using butorphanol as an epidural analgesic during labor.AIM To assess butorphanol's safety and efficacy for epidural labor analgesia.METHODS The PubMed,Cochrane Library,EMBASE,Web of Science,China National Knowledge Infrastructure,and Google Scholar databases will be searched from inception.Other types of literature,such as conference abstracts and references to pertinent reviews,will also be reviewed.We will include randomized controlled trials comparing butorphanol with other opioids combined with local anesthetics for epidural analgesia during labor.There will be no language restrictions.The primary outcomes will include the visual analog scale score for the first stage of labor,fetal effects,and Apgar score.Two independent reviewers will evaluate the full texts,extract data,and assess the risk of bias.Publication bias will be evaluated using Egger's or Begg's tests as well as visual analysis of a funnel plot,and heterogeneity will be evaluated using the Cochran Q test,P values,and I2 values.Meta-analysis,subgroup analysis,and sensitivity analysis will be performed using RevMan software version 5.4.This protocol was developed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)Protocols statement,and the PRISMA statement will be used for the systematic review.RESULTS This study provides reliable information regarding the safety and efficacy of using butorphanol as an epidural analgesic during labor.CONCLUSION To support clinical practice and development,this study provides evidence-based findings regarding the safety and efficacy of using butorphanol as an epidural analgesic during labor.

Advances in epidural labor analgesia:Effectiveness and treatment strategies of butorphanol

In this editorial,we provide a critical review of the article by Tang et al published in the World J Clin Cases,focusing on the utilization of butorphanol for epidural analgesia during labor.Our discussion encompasses recent research developments in epidural labor analgesia,specifically highlighting the current status of clinical applications of butorphanol and associated treatment approaches.Epidural analgesia is widely acknowledged as the primary method for pain management during labor,offering effective and prolonged pain relief while allowing mothers to remain alert and actively participate in the delivery process.Among the various drugs utilized for epidural labor analgesia,butorphanol has received increasing attention due to its potential efficacy and distinctive pharmacological properties.As a synthetic opioid analgesic,butorphanol exhibits both agonistic and antagonistic activity on opioid receptors,striking a balance between analgesia and minimizing side effects.Nevertheless,the safety and efficacy of butorphanol in epidural labor analgesia remains controversial.While certain studies have reported positive outcomes with butorphanol,including effective pain relief and a reduced incidence of side effects,others have raised concerns about its safety and efficacy compared to traditional opioids or alternative analgesics.In addition,the optimal dosing strategy and regimen of butorphanol as an adjuvant in epidural labor analgesia still need to be verified.Through comprehensive synthesis and analysis of existing literature,we aim to evaluate the current evidence regarding the use of butorphanol for epidural labor analgesia,delineate areas of consensus and controversy,and propose future avenues for research and clinical practice in this domain.

Efficacy and safety of propofol target-controlled infusion combined with butorphanol for sedated colonoscopy

BACKGROUND Propofol is a short-acting,rapid-recovering anesthetic widely used in sedated colonoscopy for the early detection,diagnosis and treatment of colon diseases.However,the use of propofol alone may require high doses to achieve the induction of anesthesia in sedated colonoscopy,which has been associated with anesthesia-related adverse events(AEs),including hypoxemia,sinus bradycardia,and hypotension.Therefore,propofol co-administrated with other anesthetics has been proposed to reduce the required dose of propofol,enhance the efficacy,and improve the satisfaction of patients receiving colonoscopy under sedation.AIM To evaluate the efficacy and safety of propofol target-controlled infusion(TCI)in combination with butorphanol for sedation during colonoscopy.METHODS In this controlled clinical trial,a total of 106 patients,who were scheduled for sedated colonoscopy,were prospectively recruited and assigned into three groups to receive different doses of butorphanol before propofol TCI:Low-dose butorphanol group(5μg/kg,group B1),high-dose butorphanol group(10μg/kg,group B2),and control group(normal saline,group C).Anesthesia was achieved by propofol TCI.The primary outcome was the median effective concentration(EC50)of propofol TCI,which was measured using the up-and-down sequential method.The secondary outcomes included AEs in perianesthesia and recovery characteristics.RESULTS The EC50 of propofol for TCI was 3.03μg/mL[95%confidence interval(CI):2.83-3.23μg/mL]in group B2,3.41μg/mL(95%CI:3.20-3.62μg/mL)in group B1,and 4.05μg/mL(95%CI:3.78-4.34μg/mL)in group C.The amount of propofol necessary for anesthesia was 132 mg[interquartile range(IQR),125-144.75 mg]in group B2 and 142 mg(IQR,135-154 mg)in group B1.Furthermore,the awakening concentration was 1.1μg/mL(IQR,0.9-1.2μg/mL)in group B2 and 1.2μg/mL(IQR,1.025-1.5μg/mL)in group B1.Notably,the propofol TCI plus butorphanol groups(groups B1 and B2)had a lower incidence of anesthesia AEs,when compared to group C.Furthermore,no significant differences were observed in the rates of AEs in perianesthesia,including hypoxemia,sinus bradycardia,hypotension,nausea and vomiting,and vertigo,among group C,group B1 and group B2.CONCLUSION The combined use with butorphanol reduces the EC50 of propofol TCI for anesthesia.The decrease in propofol might contribute to the reduced anesthesia-related AEs in patients undergoing sedated colonoscopy.

Effect of anesthesia induction with butorphanol on postoperative nausea and vomiting:A randomized controlled trial

BACKGROUND Postoperative nausea and vomiting(PONV)are common complications that affect the recovery and well-being of elderly patients undergoing gastrointestinal laparoscopic surgery.AIM To investigate the effect of butorphanol on PONV in this patient population.METHODS A total of 110 elderly patients(≥65 years old)who underwent gastrointestinal laparoscopic surgery were randomly assigned to receive butorphanol(40μg/kg)or sufentanil(0.3μg/kg)during anesthesia induction in a 1:1 ratio.The measured outcomes included the incidence of PONV at 48 h after surgery,intraoperative dose of propofol and remifentanil,Bruggrmann Comfort Scale score in the postanesthesia care unit(PACU),number of compressions for postoperative patientcontrolled intravenous analgesia(PCIA),and time to first flatulence after surgery.RESULTS The results revealed a noteworthy reduction in the occurrence of PONV at 24 h after surgery in the butorphanol group,when compared to the sufentanil group(T1:23.64%vs 5.45%,T2:43.64%vs 20.00%,P<0.05).However,no significant variations were observed between the two groups,in terms of the clinical characteristics,such as the PONV or motion sickness history,intraoperative and postoperative 48-h total infusion volume and hemodynamic parameters,intraoperative dose of propofol and remifentanil,number of postoperative PCIA compressions,time until the first occurrence of postoperative flatulence,and incidence of PONV at 48 h post-surgery(all,P>0.05).Furthermore,patients in the butorphanol group were more comfortable,when compared to patients in the sufentanil group in the PACU.CONCLUSION The present study revealed that butorphanol can be an efficacious substitute for sufentanil during anesthesia induction to diminish PONV within 24 h following gastrointestinal laparoscopic surgery in the elderly,simultaneously improving patient comfort in the PACU.

Efficacy and safety of transnasal butorphanol for pain relief after anal surgery

AIM:To compare the analgesic properties and efficacy of transnasal butorphanol with intramuscular meperidine after anal surgery.METHODS: Sixty patients who underwent fistulectomy were enrolled in the study from January 2006 to December 2007. They were randomly divided into transnasal butorphanol (n=30) or intramuscular meperidine (n=30) treatment groups. Assessment of postoperative pain was made using a visual analogue scale (VAS). The VAS score was recorded 6 h after the completion of surgery, before receiving the first dose of analgesic, 60 min after analgesia and the next morning. Any adverse clinical effects such as somnolence, dizziness, nausea or vomiting were recorded. Satisfaction with narcotic efficacy, desire to use the particular analgesic in the future and any complaints were recorded by patients using questionnaires before being discharged.RESULTS: Forty-two men and eighteen women were included in the study. There were no significant differences in VAS scores between the groups within 24 h. Length of hospital stay and the incidence of adverse effects between the groups were similar. In addition, most patients were satisfied with butorphanol nasal spray and wished to receive this analgesic in the future, if needed.CONCLUSION: Butorphanol nasal spray is effective for the relief of pain after fistulectomy. However, it offered patients more convenient usage and would be suitable for outpatients.

Combined lumbar muscle block and perioperative comprehensive patient-controlled intravenous analgesia with butorphanol in gynecological endoscopic surgery

BACKGROUND Laparoscopic surgery has become a common surgical approach for the clinical treatment of intra-abdominal lesions in recent years.We hypothesized that lumbar block with postoperative patient-controlled intravenous analgesia(PCIA)by butorphanol after gynecological surgery under general anesthesia would be more effective than PCIA by butorphanol alone.AIM To investigate the effect of lumbar block with PCIA by butorphanol after gynecological surgery under general anesthesia.METHODS This study assessed 120 women scheduled for laparoscopic surgery at our hospital between May 2017 and May 2020.They were divided using a random number table into a research group(those who received quadratus lumborum block combined with PCIA analgesia by butorphanol)and a control group(those who received only PCIA analgesia by butorphanol),with 60 patients in each group.Demographic factors,visual analog scale scores for pain,serum inflammatory markers,PCIA compressions,Ramsay scores,and adverse events were compared between groups using a t-test,analysis of variance,orχ2 test,as appropriate.RESULTS There were no significant differences in demographic factors between groups(all P>0.05).The visual analog scale scores of the research group in the resting state 12 h and 24 h postoperatively were significantly lower than those of the control group(P<0.05).Two hours after surgery,there were no significant differences in the levels of serum tumor necrosis factor-α,interleukin(IL)-6,or IL-8 between groups(P>0.05).The serum tumor necrosis factor-αlevels of the research group 24 h postoperatively were significantly lower than those of the control group(P<0.05).The levels of serum IL-6 and IL-8 in the study group 24 h and 48 h postoperatively were significantly lower than those in the control group(P<0.05).CONCLUSION Lumbar block with PCIA with butorphanol after gynecological surgery under general anesthesia significantly improves the analgesic effect and reduces the degree of inflammation,instances of PCIA compression,and adverse reactions.

Preemptive analgesia with butorphanol in psychotic patients following modified electroconvulsive therapy A randomized controlled trial

BACKGROUND： Preemptive .analgesia involves introducing an analgesic prior to the onset of pain stimulation to prevent sensitizing the nervous system to subsequent stimuli that could amplify pain. OBJECTIVE： To treat psychiatric patients with intravenous （i.v.） injection of butorphanol prior to modified electroconvulsive therapy, and to observe its effect on alleviating myalgia after treatment and adverse reactions. DESIGN： A randomized controlled observation. SETTING： Renmin Hospital of Wuhan University. PARTICIPANTS： A total of 120 psychiatric patients, who accepted modified electroconvulsive therapy, were selected from the Mental Health Center of Wuhan University from June to September in 2006. All patients corresponded to the Chinese Classification and Diagnostic Criteria of Mental Disorders, and those with diseases of heart, liver, lung and kidney, glaucoma, intracranial hypertension, hyperthyreosis, and hyperkalemia were excluded. The patients were randomly divided into a control group （n = 60） and treatment group （n = 60）. In the control group, there were 42 males and 18 females, aged 17-50 years, with a mean age of （34 ± 11） years. The patients weighed 50-70 kg, with a mean body mass of （63 ± 18） kg. In the treatment group, there were 40 males and 20 females, aged 20-54 years, with a mean age of （36 ± 13） years. The patients weighed 48-72 kg, with a mean body mass of （64 ± 16） kg. Approval was obtained from the Hospital＇s Ethics Committee. Informed consents were obtained from the patients＇ relatives. A SPECTRUM5000Q multifunctional mobile electroconvulsive therapy apparatus （CORPERATION, USA） was used. METHODS： （1） Treatments： In the control group, the patients were anesthetized by i.v. injection of propofol （AstraZeneca, Italy, No.CN309） containing 0.075% efedrina, and then modified electroconvulsive therapy was performed. Circulation, respiration, and firing of brain electrical activity were continuously monitored. In the treatment group, the patients were i.v. injected with 1 mg of butorphanol tartrate parenteral solution （Jiangsu Hengrui Medicine Co., Ltd., No.05100732） 5 minutes prior to anesthesia; the remaining treatments were the same as in the control group. （2） Evaluations： myalgia conditions were assessed 6 hours after the patients opened their eyes. The patients were evaluated by a visual analogue scale and Ramsay sedation scale immediately, and at 3 minutes and 6 hours after they opened their eyes. MAIN OUTCOME MEASURES： （1） Conditions of myalgia. （2） Scores of visual analogue scale and Ramsay sedation scale. RESULTS： All 120 psychiatric patients were involved in the final analysis. （1） Conditions of myalgia： 6 hours after modified electroconvulsive therapy, 22 patients in the control group and 1 patient in the treatment group complained of myalgia, which resulted in a significant difference between the two groups （P 〈 0.05）. （2） Scores of visual analogue scale and Ramsay sedation scale： the scores of visual analogue scale at 30 minutes and 6 hours after opening eyes were significantly lower in the treatment group than the control group （P 〈 0.05）, and the scores of Ramsay sedation scale were not significantly different between the two groups （P 〉 0.05）. CONCLUSION： Preemptive analgesia by butorphanol can effectively alleviate modified electroconvulsive therapy-induced myalgia, without adverse reactions.

Combination of Dexmedetomidine and Butorphanol Optimized Sedation in Drug-Induced Sleep Endoscopy: A Randomized, Double-Blind Trial

Objective:Drug-induced sleep endoscopy(DISE)allows for the evaluation of dynamic airway collapse in patients with obstructive sleep apnea.However,a standardized sedation regimen for DISE is not yet available.This study aimed to investigate the safety profiles and efficacies of dexmedetomidine combined with butorphanol for DISE.Methods:Sixty patients with obstructive sleep apnea scheduled to undergo DISE were randomly divided into Group D and Group DB.All recipients were initially given intravenous butorphanol(1 mg)(Group DB)or saline(Group D).Subsequently,both groups were sedated using a loading dose of 1.0 pg/kg/h of dexmedetomidine.Hemodynamic and respiratory parameters,the time to attain sufficient sedation,wakeup time,and adverse events during DISE were recorded.Results:Compared with Group D,the time until sufficient sedation and wakeup time in Group DB were significantly reduced.A higher performer satisfaction level was achieved in Group DB.Patients in Group DB showed a higher incidence of bradycardia compared with Group D.However,the bradycardia resolved spontaneously in both groups without any treatment.There was no instance of cough,hypotension,arrhythmia,nausea or vomiting in either group.Conclusion:Compared to dexmedetomidine alone,a small dose of butorphanol infusion(1 mg)as an adjunct treatment to dexmedetomidine during DISE can reduce the dosage of dexmedetomidine,shorten the time until sufficient sedation and enhance the performer satisfaction level.This synergistic combination could be a promising sedation regimen for DISE in terms of procedural convenience and patient safety.

N-methyl-D-aspartate receptor expression in the spinal dorsal horn of a rat model of formalin-induced inflammatory pain following intrathecal injection of butorphanol

Clinical and animal experiments have proved that intrathecal injection of butorphanol has an analgesic effect. However, whether the analgesic effect is associated with activation of the N-methyI-D-aspartate （NMDA） receptor remains unclear. This study presumed that intrathecal injection of butorphanol has an analgesic effect on formalin-induced inflammatory pain in rats, and its analgesic effect is associated with inhibition of NMDA receptors. Concurrently, ketamine was injected into the intrathecal space, which is a non-competitive NMDA receptor antagonist, to determine the analgesic mechanism of butorphanol. The total reflection time in phase 1 and phase 2 of rat hind paws carding action was reduced when the butorphanol dose was increased to 25 μg, or a low dose of butorphanol was combined with ketamine. Intrathecal injection of a high dose of butorphanol alone or a low dose of butorphanol combined with ketamine can remarkably reduce NMDA receptor expression in the Ls spinal dorsal hom of formalin-induced pain rats. The results suggest that intrathecal injection of butorphanol has analgesic effects on formalin-induced inflammatory pain, and remarkably reduces NMDA receptor expression in the rat spinal dorsal horn Ketamine strengthens this analgesic effect. The analgesic mechanism of intrathecal injection of butorphanol is associated with inhibition of NMDA receptor activation.

Study on Analgesia and Sedation of Butorphanol Tartrate Combined with Dexmedetomidine in Severe Cerebral Hemorrhage for Patients with Mechanical Ventilation

Objective: To analyze the effect and advantages in analgesia and sedation of butorphanol tartrate combined with dexmedetomidine in severe cerebral hemorrhage for patients with mechanical ventilation. Methods: 120 patients with severe cerebral hemorrhage requiring analgesia and sedation were randomly selected and divided into two groups: the control group (dexmedetomidine treatment group) and the test group (dexmedetomidine combined with butorphanol tartrate). Two groups of patients with different drugs were analyzed. Results: The average dose of dexmedetomidine (microgram) and the total adverse events (Times) in the test group were significantly lower than those in the control group within 48 hours (P < 0.05);The dose of Butorphanol in the test group was small, and the patients in the control group used other opioid analgesics to pump more significantly. Conclusion: Using butorphanol tartrate combined with dexmedetomidine can achieve the same sedative effect and enhance the analgesic effect as using dexmedetomidine alone with less dose of dexmedetomidine, and the clinical effect is significant. It also solves the problem that adverse reactions such as blood pressure change and bradycardia are easy to occur when using large dose of dexmedetomidine and the infusion speed is fast in clinical application, and significantly reduces the incidence of adverse reactions. It is worthy of clinical application.

环泊酚、丙泊酚分别联合布托啡诺麻醉在老年无痛胃肠镜检查中的应用比较

目的:比较环泊酚、丙泊酚分别联合布托啡诺麻醉在老年无痛胃肠镜检查中的应用。方法:选取无痛胃肠镜检查的老年患者160例,使用随机信封法分为环泊酚组(80例)和丙泊酚组(80例)。环泊酚组采用环泊酚复合布托啡诺麻醉,丙泊酚组采用丙泊酚复合布托啡诺麻醉。比较两组麻醉诱导前(T_(0))、睫毛反射消失后(T_(1))和定向力恢复时(T_(2))的平均动脉压(MAP)、心率(HR)和血氧饱和度(SpO_(2))。比较两组苏醒时间和术后简易精神状态量表(MMSE)评分。比较两组离开麻醉监测治疗室(PACU)即刻(T_(3))、离开PACU后1 h(T_(4))和离开PACU后2 h时(T_(5))的视觉模拟量表(VAS)评分。比较两组注射痛、心律失常等不良反应发生情况。结果:环泊酚组T_(1)时间点MAP、HR和SpO_(2)高于丙泊酚组(均P<0.05)。环泊酚组苏醒时间及各时间点MMSE评分与丙泊酚组比较无统计学差异(均P>0.05)。两组各时间点VAS评分比较无统计学差异(均P>0.05)。环泊酚组注射痛发生率低于丙泊酚组(P<0.05)。环泊酚组心律失常发生率、血压异常率、呼吸抑制率、恶心呕吐率与丙泊酚组比较无统计学差异(均P>0.05)。结论:老年患者无痛胃肠镜检查中使用环泊酚复合布托啡诺麻醉能取得满意的麻醉效果,患者苏醒迅速,且有助于维持循环呼吸稳定,减少不良反应。

酒石酸布托啡诺联合丙泊酚用于无痛胃镜下ESD患者的有效性与安全性观察

目的研究酒石酸布托啡诺联合丙泊酚对无痛胃镜下内镜黏膜下剥离术(ESD)患者的有效性和安全性。方法90例拟行无痛胃镜下ESD治疗患者,采用随机数字表法分为B1组、B2组及S组,每组30例。B1组、B2组分别于丙泊酚麻醉诱导前5 min给予10、20μg/kg酒石酸布托啡诺,S组于丙泊酚麻醉诱导前5 min给予等量生理盐水。比较三组的麻醉苏醒时间、丙泊酚用量、体动发生率,麻醉诱导前(T1)、置镜前(T2)、置镜中(T3)、出镜后(T4)的平均动脉压(MAP)、心率(HR)、脉搏氧饱和度(SpO_(2)),低氧血症发生率及不良反应发生率。结果B1组麻醉苏醒时间(6.00±0.56)min短于B2组的(6.77±0.37)min、S组的(6.25±0.33)min,B2组麻醉苏醒时间长于S组(P<0.05);B1组、B2组丙泊酚用量分别为(240.65±13.36)、(200.36±14.58)mg,均少于S组的(270.44±17.38)mg,B1组丙泊酚用量多于B2组(P<0.05);实验过程中S组有10例出现体动,B1组出现3例体动、B2组出现2例体动,B1组、B2组体动发生率分别为10.0%、6.7%,低于S组的33.3%(P<0.05)。T1时,三组患者的HR、MAP、SpO_(2)比较,差异无统计学意义(P>0.05)。与T1时比较,三组患者T2、T3、T4时的MAP均下降(P<0.05);但B1组、B2组患者T2时的MAP均高于S组(P<0.05)。与T1时比较,S组患者T2、T3、T4时的HR均下降,B1组、B2组患者T2、T3时的HR均下降(P<0.05);但B1组、B2组患者T2时的HR高于S组(P<0.05)。与T1时比较,三组患者T2、T3时的SpO_(2)均下降(P<0.05);但B1组、B2组患者T2、T3时的SpO_(2)高于S组(P<0.05)。S组低氧血症发生率26.7%(8/30)明显高于B1组的6.7%(2/30)、B2组的3.3%(1/30)(P<0.05);B2组头晕发生率26.7%(8/30)明显高于S组的0、B1组的6.7%(2/30)(P<0.05)。结论10μg/kg酒石酸布托啡诺复合丙泊酚可以安全、有效地应用于无痛胃镜下ESD患者中,有效提升麻醉效果的同时,可减少不良反应的发生。

布托啡诺调节Wnt/β-catenin信号通路对肺癌细胞增殖迁移和血管生成的影响

目的:探讨布托啡诺调节Wnt/β-catenin信号通路对肺癌细胞增殖、迁移和血管生成的影响。方法:将肺癌H1299细胞分为对照组、布托啡诺低、高剂量组、布托啡诺高剂量+LiCl(Wnt/β-catenin信号通路激活剂)组、FH535组(Wnt/β-catenin信号通路抑制剂)。克隆形成实验检测细胞克隆能力;Transwell实验检测细胞迁移和侵袭;流式细胞术检测细胞凋亡率;血管拟态形成实验观察血管生成情况;western blot检测VEGF-A、VE-cadherin、Bcl-2、Bax、MMP-9、β-catenin、c-Myc和cyclin D1蛋白表达。结果:对照组H1299细胞管腔结构完整;与对照组相比,布托啡诺低、高剂量组和FH535组H1299细胞克隆形成率、细胞迁移和侵袭个数、管腔数量及VEGF-A、VE-cadherin、Bcl-2、MMP-9、β-catenin、c-Myc和cyclin D1蛋白表达降低,细胞凋亡率和Bax蛋白表达升高(P<0.05);LiCl可部分逆转布托啡诺对H1299细胞恶性生物学行为的抑制(P<0.05);FH535组H1299细胞各项检测指标与布托啡诺高剂量组处于同一水平(P<0.05)。结论:布托啡诺能够诱导肺癌细胞凋亡,阻滞迁移、增殖和血管生长,进而阻止肺癌的发生发展,其机制与阻断Wnt/β-catenin信号通路激活相关。

布托啡诺PCIA联合超声引导下弓状韧带上腰方肌阻滞对剖宫产术后镇痛的应用效果评价

目的分析布托啡诺静脉自控镇痛(PCIA)联合超声引导下弓状韧带上腰方肌阻滞(QLB-LSAL)在剖宫产术后镇痛中的应用效果。方法选取2022年12月至2023年10月期间于本院行剖宫产手术的患者60例,按照随机数字表法予以分组。对照组采用布托啡诺PCIA进行术后镇痛,在此基础上研究组联合超声引导下QLB-LSAL。针对两组术后首次按压镇痛泵时间、48 h布托啡诺消耗量、镇痛泵追加次数、术后不同时间段静息状态与运动状态的视觉模拟量表(VAS)评分、离床活动时间、泌乳时间、肛门恢复排气时间、布鲁格曼舒适度量表(BCS),以及镇痛相关不良反应情况予以比较。结果与对照组结果对比,研究组首次按压镇痛泵时间更长(P<0.05),术后48h布托啡诺消耗量、镇痛泵追加次数更低(P<0.05)。与对照组相比,研究组术后6h、12 h、24 h、48 h静息状态、运动状态时的VAS评分更低(P<0.05)。与对照组结果相比,研究组离床活动时间、泌乳时间、恢复肛门排气时间更短(P<0.05),BCS评分更高(P<0.05)。在镇痛不良反应发生率比较中,两组结果无明显差异(P>0.05)。结论布托啡诺PCIA联合超声引导下QLB-LSAL能够有效提高剖宫产术后镇痛效果,减少布托啡诺用量,保障产妇的舒适度,促进产后康复进程。

布托啡诺复合右美托咪定用于下肢神经阻滞麻醉的临床效果观察

目的探讨在下肢神经阻滞麻醉中采用布托啡诺复合右美托咪定的临床效果。方法80例进行下肢手术的患者,采用随机数字表法分成对照组和研究组,每组40例。两组患者术中均采取下肢神经阻滞麻醉,对照组采用布托啡诺,研究组采用布托啡诺复合右美托咪定。对比两组麻醉阻滞时间,不同时间段(术前、神经阻滞期间、术后)心率、平均动脉压,手术前后应激指标[去甲肾上腺素(NE)、皮质醇(Cor)以及肾上腺素(E)],不良反应发生率。结果与对照组相比,研究组麻醉阻滞起效时间较短,麻醉阻滞持续时间、镇痛持续时间均较长(P<0.05)。神经阻滞期间,对照组心率为(86.54±4.15)次/min,平均动脉压为(93.54±4.34)mm Hg(1 mm Hg=0.133 kPa);研究组心率为(63.54±3.24)次/min,平均动脉压为(90.61±4.51)mm Hg,与对照组相比,研究组心率、平均动脉压较低(t=27.629、2.961,P<0.05)。术后,对照组心率为(73.54±3.34)次/min,平均动脉压为(97.55±5.12)mm Hg;研究组心率为(64.05±3.18)次/min,平均动脉压为(92.34±4.39)mm Hg,与对照组相比,研究组心率、平均动脉压较低(t=13.015、4.886,P<0.05)。术后,对照组NE为(451.25±25.12)ng/L,Cor为(844.15±31.15)nmol/L,E为(741.25±30.15)pmol/L;研究组NE为(344.85±24.05)ng/L,Cor为(721.35±28.46)nmol/L,E为(552.41±23.28)pmol/L,两组应激指标均较术前有所升高,但与对照组相比,研究组NE、Cor、E较低(t=19.350、18.407、31.354,P<0.05)。研究组不良反应发生率5.00%低于对照组的22.50%(P<0.05)。结论下肢神经阻滞麻醉中采用布托啡诺复合右美托咪定效果显著,可缩短麻醉阻滞时间,稳定术中应激指标,减少麻醉不良反应发生率,安全性较高。

布托啡诺调节PI3K/AKT/mTOR信号通路对膀胱癌细胞恶性生物学行为的影响

目的:探讨布托啡诺调节磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/AKT/mTOR)信号通路对膀胱癌细胞恶性生物学行为的影响。方法:体外培养膀胱癌细胞T24;将细胞分为对照组、布托啡诺低剂量组(1 ng/mL)、布托啡诺中剂量组(10 ng/mL)、布托啡诺高剂量组(100 ng/mL)、激活剂组(100 ng/mL布托啡诺+PI3K激动剂Recilisib 10μmol/L)、抑制剂组(100 ng/mL布托啡诺+PI3K抑制剂LY294002 50μmol/L)。CCK-8实验检测细胞增殖;流式细胞术检测细胞凋亡;Transwell检测细胞迁移和侵袭;Western blot检测细胞PI3K/AKT/mTOR信号通路相关蛋白表达;并构建异种移植肿瘤模型,称量肿瘤质量,计算肿瘤体积。结果:与对照组比较,布托啡诺低剂量、布托啡诺中剂量、布托啡诺高剂量组T24细胞OD_(450)值和迁移、侵袭细胞数目及p-PI3K、p-AKT、p-mTOR蛋白表达显著降低,细胞凋亡率显著升高,且呈剂量依赖性(P<0.05);激活剂减弱了布托啡诺抑制T24细胞增殖、迁移和侵袭,促进细胞凋亡的作用,抑制剂加强了布托啡诺抑制T24细胞增殖、迁移和侵袭,促进细胞凋亡的作用。与裸鼠对照组相比,裸鼠布托啡诺低剂量、裸鼠布托啡诺中剂量、裸鼠布托啡诺高剂量组肿瘤体积和质量显著减小,且呈现剂量依赖性(P<0.05);与裸鼠布托啡诺高剂量组比较,裸鼠激活剂组肿瘤体积、肿瘤质量显著增大(P<0.05),裸鼠抑制剂组肿瘤体积、肿瘤质量显著减小(P<0.05)。结论:布托啡诺通过抑制PI3K/AKT/mTOR信号通路抑制膀胱癌细胞增殖、迁移和侵袭。

脑电双频谱指数监测下布托啡诺复合丙泊酚对老年人超声支气管镜检查的影响

目的探讨脑电双频谱指数监测下布托啡诺复合丙泊酚对老年人超声支气管镜检查的影响。方法选择2022年6月至2023年4月期间于本院明确诊断的实施无痛超声支气管镜检查的老年患者180例作为研究对象,随机分为Ⅰ组(单纯丙泊酚组)、Ⅱ组(舒芬太尼复合丙泊酚组)和Ⅲ组(布托啡诺复合丙泊酚组),每组各60例。比较各组麻醉前后血流动力学指标、麻醉、镇痛、镇静效果及不良反应。结果Ⅲ组镜入喉腔和镜检结束时平均动脉压(MAP)和心率(HR)、丙泊酚用量、麻醉起效时间、镜检时间、苏醒时间及不良反应发生率均低于Ⅰ、Ⅱ组,镜入喉腔和镜检结束时SpO_(2)及Ramsay评分高于Ⅰ、Ⅱ组(P<0.05)。结论布托啡诺复合丙泊酚诱导血流动力学指标稳定,能够提升患者舒适度,具有较好的麻醉、镇痛及镇静效果,且术后不良反应更少,更适用于老年超声支气管镜的检查。

酒石酸布托啡诺复合罗哌卡因用于剖宫产术后镇痛的效果

目的探讨酒石酸布托啡诺复合罗哌卡因用于剖宫产术后镇痛的效果。方法选取2021年4月至2022年6月滨州市中心医院收治的80例剖宫产产妇为研究对象,采用奇偶数法分为对照组和观察组,每组40例。对照组采用罗哌卡因术后镇痛,观察组采用酒石酸布托啡诺复合罗哌卡因术后镇痛,比较两组镇痛效果。结果观察组术后2、8、12、24 h疼痛评分低于对照组(P<0.05);观察组术后24 h内自控镇痛次数少于对照组,术毕至首次自控镇痛时间长于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论酒石酸布托啡诺复合罗哌卡因用于剖宫产术后镇痛的效果显著,值得推广。

联合布托啡诺时环泊酚在老年患者无痛胃镜检查中的有效剂量及安全性

目的探讨联合布托啡诺时环泊酚用于老年患者无痛胃镜检查的半数有效剂量(ED_(50))和95%有效剂量(ED_(95))。方法选择择期行胃镜检查的老年患者27例,均给予静脉注射布托啡诺5μg/kg至少30 s,3 min后静脉注射环泊酚至少30 s;当睫毛反射消失或者警觉/镇静评分(MOAA/S)<1分时进行胃镜检查。环泊酚最初剂量设为0.2 mg/kg,采用改良序贯等差法测定;若胃镜置入发生阳性反应,则下例患者剂量增加1级,反之则剂量减少1级,相邻剂量梯度为0.05 mg/kg。将胃镜置入发生阳性反应定义为:胃镜进入咽喉部时发生呛咳、吞咽或肢体动作。整个研究过程中,若环泊酚剂量调整有7次折返,试验终止。计算复合布托啡诺时环泊酚对无痛胃镜检查的ED_(50)、ED_(95)和相应的95%可信区间(95%CI)。结果复合布托啡诺时,环泊酚对老年患者无痛胃镜检查的ED_(50)为0.253 mg/kg(95%CI:0.219~0.290),ED_(95)为0.328 mg/kg(95%CI:0.290~0.521)。结论复合布托啡诺时,环泊酚用于老年患者无痛胃镜检查ED_(50)为0.253 mg/kg,ED_(95)为0.328 mg/kg。

布托啡诺在无痛胃镜中的应用及研究进展

近年来,我国胃肠道疾病的发病率逐渐增加,无痛胃镜检查则是最可靠、最常用的诊断方法。布托啡诺与丙泊酚联合应用,具有良好的镇痛作用,且不良反应少,已广泛应用于无痛胃镜检查中。但是对于不同年龄阶段患者布托啡诺的应用剂量是否一致仍未可知,本研究旨在探索布托啡诺在不同年龄阶段患者接受无痛胃镜的应用剂量,为临床用药提供参考依据。